The American Journal of Medicine
Volume 118, Issue 12, Supplement 2 , Pages 136-141 , 19 December 2005

Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century

  • Patricia A. Ganz, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Patricia A. Ganz, MD, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, California 90095-6900.

References 

  1. Ganz PA . Menopause and breast cancer (symptoms, late effects, and their management) . Semin Oncol . 2001;28:274–283
  2. Partridge AH , Burstein HJ , Winer EP . Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer . [published correction appears in J Natl Cancer Inst. 2002;94:866 and J Natl Cancer Inst Monogr. 2003;(31):131] J Natl Cancer Inst Monogr . 2001;30:135–142
  3. National Institutes of Health Consensus Development Panel . National Institutes of Health Consensus Development Conference statement (adjuvant therapy for breast cancer, November 1–3, 2000) . J Natl Cancer Inst . 2001;30:5–15
  4. Goodwin PJ , Ennis M , Pritchard KI , Trudeau M , Hood N . Risk of menopause during the first year after breast cancer diagnosis . J Clin Oncol . 1999;17:2365–2370
  5. Burstein HJ , Winer EP . Primary care for survivors of breast cancer . N Engl J Med . 2000;343:1086–1094
  6. Narod SA , Offit K . Prevention and management of hereditary breast cancer . J Clin Oncol . 2005;23:1656–1663
  7. Jemal A , Murray T , Ward E , et al.   Cancer statistics, 2005 . CA Cancer J Clin . 2005;55:10–30
  8. Dickson RB , Russo J . Biochemical control of breast development . In:  Harris JR ,  Lippman ME ,  Morrow M ,  Osborne CK editor. Diseases of the Breast . Philadelphia: Lippincott Williams & Wilkins; 2000;p. 15–31
  9. Russo J , Russo IH . Genotoxicity of steroidal estrogens . Trends Endocrinol Metab . 2004;15:211–214
  10. Colditz GA . Postmenopausal estrogens and breast cancer . J Soc Gynecol Investig . 1996;3:50–56
  11. Schairer C . Progesterone receptors—animal models and cell signalling in breast cancer (implications for breast cancer of inclusion of progestins in hormone replacement therapies) . Breast Cancer Res . 2002;4:244–248
  12. Clemons M , Goss P . Estrogen and the risk of breast cancer . N Engl J Med . 2001;344:276–285
  13. Hankinson SE , Colditz GA , Willett WC . Towards an integrated model for breast cancer etiology (the lifelong interplay of genes, lifestyle, and hormones) . Breast Cancer Res . 2004;6:213–218
  14. King MC , Marks JH , Mandell JB . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 . Science . 2003;302:643–646
  15. Early Breast Cancer Trialists’ Collaborative Group . Tamoxifen for early breast cancer . Cochrane Database Syst Rev . 2001;1:CD000486
  16. Alberg AJ , Lam AP , Helzlsouer KJ . Epidemiology, prevention, and early detection of breast cancer . Curr Opin Oncol . 1999;11:435–441
  17. Goss PE , Ingle JN , Martino S , et al.   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer . N Engl J Med . 2003;349:1793–1802
  18. Winer EP , Hudis C , Burstein HJ , et al.   American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer (status report 2004) . J Clin Oncol . 2005;23:619–629
  19. Castiglione-Gertsch M , O’Neill A , Price KN , et al.  International Breast Cancer Study Group   Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer (a randomized trial) . J Natl Cancer Inst . 2003;95:1833–1846
  20. Ganz PA , Greendale GA , Petersen L , Kahn B , Bower JE . Breast cancer in younger women (reproductive and late health effects of treatment) . J Clin Oncol . 2003;21:4184–4193
  21. Rossouw JE , Anderson GL , Prentice RL , et al.  Writing Group for the Women’s Health Initiative Investigators   Risks and benefits of estrogen plus progestin in healthy postmenopausal women (principal results from the Women’s Health Initiative randomized controlled trial) . JAMA . 2002;288:321–333
  22. Anderson GL , Limacher M , Assaf AR , et al.   Effects of conjugated equine estrogen in postmenopausal women with hysterectomy (the Women’s Health Initiative randomized controlled trial) . JAMA . 2004;291:1701–1712
  23. van de Vijver MJ , He YD , ’t Veer LJ , et al.   A gene-expression signature as a predictor of survival in breast cancer . N Engl J Med . 2002;347:1999–2009
  24. Paik S , Shak S , Tang G , et al.   A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer . N Engl J Med . 2004;351:2817–2826
  25. Ganz PA , Greendale GA . Menopause and breast cancer (addressing the secondary health effects of adjuvant chemotherapy) . J Clin Oncol . 2001;19:3303–3305
  26. Ganz PA . Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life . J Natl Cancer Inst Monogr . 2001;30:130–134
  27. Greendale GA , Petersen L , Zibecchi L , Ganz PA . Factors related to sexual function in postmenopausal women with a history of breast cancer . Menopause . 2001;8:111–119
  28. Meyerowitz BE , Desmond KA , Rowland JH , Wyatt GE , Ganz PA . Sexuality following breast cancer . J Sex Marital Ther . 1999;25:237–250
  29. Ganz PA , Rowland JH , Meyerowitz BE , Desmond KA . Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors . Recent Results Cancer Res . 1998;152:396–411
  30. Ganz PA , Rowland JH , Desmond K , Meyerowitz BE , Wyatt GE . Life after breast cancer (understanding women’s health-related quality of life and sexual functioning) . J Clin Oncol . 1998;16:501–514
  31. Crandall C , Petersen L , Ganz PA , Greendale GA . Association of breast cancer and its therapy with menopause-related symptoms . Menopause . 2004;11:519–530
  32. Avis NE , Stellato R , Crawford S , Johannes C , Loncope C . Is there an association between menopause status and sexual functioning? . Menopause . 2000;7:297–309
  33. Ganz PA , Desmond KA , Belin TR , Meyerowitz BE , Rowland JH . Predictors of sexual health in women after a breast cancer diagnosis . J Clin Oncol . 1999;17:2371–2380
  34. Ganz PA , Kwan L , Stanton AL , et al.   Quality of life at the end of primary treatment of breast cancer (first results from the moving beyond cancer randomized trial) . J Natl Cancer Inst . 2004;96:376–387
  35. Day R , Ganz PA , Costantino JP , Cronin WM , Wickerham DL , Fisher B . Health-related quality of life and tamoxifen in breast cancer prevention (a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study) . J Clin Oncol . 1999;17:2659–2669
  36. Ganz PA , Greendale GA , Petersen L , Zibecchi L , Kahn B , Belin TR . Managing menopausal symptoms in breast cancer survivors (results of a randomized controlled trial) . J Natl Cancer Inst . 2000;92:1054–1064
  37. Goldberg RM , Loprinzi CL , O’Fallon JR , et al.   Transdermal clonidine for ameliorating tamoxifen-induced hot flashes . J Clin Oncol . 1994;12:155–158
  38. Loprinzi CL , Michalak JC , Quella SK , et al.   Megestrol acetate for the prevention of hot flashes . N Engl J Med . 1994;331:347–352
  39. Barton DL , Loprinzi CL , Quella SK , et al.   Prospective evaluation of vitamin E for hot flashes in breast cancer survivors . J Clin Oncol . 1998;16:495–500
  40. Loprinzi CL , Abu-Ghazaleh S , Sloan JA , et al.   Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer . J Clin Oncol . 1997;15:969–973
  41. Loprinzi CL , Kugler JW , Sloan JA , et al.   Venlafaxine in management of hot flashes in survivors of breast cancer (a randomised controlled trial) . Lancet . 2000;356:2059–2063
  42. Loprinzi CL , Stearns V , Barton D . Centrally active menopausal hot flash therapies . Am J Med . 2005;118(suppl 12B):118S–123S
  43. Carpenter JS , Neal JG . Other complementary and alternative medicine modalities (acupuncture, magnets, reflexology, and homeopathy) . Am J Med . 2005;118(suppl 12B):109S–117S
  44. Low Dog T . Menopause (a review of botanical dietary supplements) . Am J Med . 2005;118(suppl 12B):98S–108S
  45. Ganz PA , Greendale GA , Kahn B , O’Leary JF , Desmond KA . Are older breast carcinoma survivors willing to take hormone replacement therapy? . Cancer . 1999;86:814–820
  46. Ballagh SA . Vaginal rings for menopausal symptom relief . Drugs Aging . 2004;21:757–766
  47. Suckling J , Lethaby A , Kennedy R . Local oestrogen for vaginal atrophy in postmenopausal women . Cochrane Database Syst Rev . 2003;4:CD001500
  48. Sherwin BB . Changes in sexual behavior as a function of plasma sex steroid levels in post-menopausal women . Maturitas . 1985;7:225–233
  49. Sherwin BB , Gelfand MM . The role of androgen in the maintenance of sexual functioning in oophorectomized women . Psychosom Med . 1987;49:397–409
  50. Berrino F , Muti P , Micheli A , et al.   Serum sex hormone levels after menopause and subsequent breast cancer . J Natl Cancer Inst . 1996;88:291–296
  51. Key T , Appleby P , Barnes I , et al.  Endogenous Hormones and Breast Cancer Collaborative Group   Endogenous sex hormones and breast cancer in postmenopausal women (reanalysis of nine prospective studies) . J Natl Cancer Inst . 2002;94:606–616
  52. Goldstat R , Briganti E , Tran J , Wolfe R , Davis SR . Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women . Menopause . 2003;10:390–398
  53. Col NF , Hirota LK , Orr RK , Erban JK , Wong JB , Lau J . Hormone replacement therapy after breast cancer (a systematic review and quantitative assessment of risk) . J Clin Oncol . 2001;19:2357–2363
  54. Holmberg PL , Anderson H . HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison (trial stopped) . Lancet . 2004;363:453–455
  55. Warner E , Plewes DB , Hill KA , et al.   Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination . JAMA . 2004;292(11):1317–1325
  56. King MC , Wieand S , Hale K , et al.   Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 (National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial) . JAMA . 2001;286:2251–2256
  57. Wooster R , Weber BL . Breast and ovarian cancer . N Engl J Med . 2003;348:2339–2347
  58. Kauff ND , Satagopan JM , Robson ME , et al.   Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation . N Engl J Med . 2002;346:1609–1615
  59. Schwartz MD , Kaufman E , Peshkin BN , et al.   Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing . J Clin Oncol . 2003;21:4034–4041
  60. Robson M , Hensley M , Barakat R , et al.   Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy . Gynecol Oncol . 2003;89:281–287

 The opinions offered at the National Institutes of Health (NIH) State-of-the Science Conference on Management of Menopause-Related Symptoms and published herein are not necessarily those of the National Institute on Aging (NIA) and the Office of Medical Applications of Research (OMAR) or any of the cosponsoring institutes, offices, or centers of the NIH. Although the NIA and OMAR organized this meeting, this article is not intended as a statement of Federal guidelines or policy.Publication of the online supplement was made possible by funding from the NIA and the National Center for Complementary and Alternative Medicine of the NIH, US Department of Health & Human Services.Supported in part by an American Cancer Society Clinical Research Professorship awarded to Dr. Ganz.

PII: S0002-9343(05)00905-8

doi: 10.1016/j.amjmed.2005.09.047

The American Journal of Medicine
Volume 118, Issue 12, Supplement 2 , Pages 136-141 , 19 December 2005

Article Tools

* Image Usage & Resolution